Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.
The FDA has given Roche its first regulatory approval for PI3K inhibitor Itovebi, clearing the drug as part of a triple therapy for certain types of locally advanced or metastatic breast ca
UK actor and TV personality Nadia Sawalha is spearheading a fundraising effort to launch an appeal against the recent rejection of a breast cancer therapy by cost-effectiveness agency NICE.
Testing for BRCA mutations linked to breast and ovarian cancers could become easier and more accessible with the help of artificial intelligence, potentially allowing earlier treatment.
Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.